Last reviewed · How we verify

Ilaprazole tablet — Competitive Intelligence Brief

Ilaprazole tablet (Ilaprazole tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Proton pump inhibitor (PPI). Area: Gastroenterology.

phase 3 Proton pump inhibitor (PPI) H+/K+-ATPase (proton pump) Gastroenterology Small molecule Live · refreshed every 30 min

Target snapshot

Ilaprazole tablet (Ilaprazole tablet) — Livzon Pharmaceutical Group Inc.. Ilaprazole is a proton pump inhibitor that suppresses gastric acid secretion by irreversibly blocking the H+/K+-ATPase enzyme in gastric parietal cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ilaprazole tablet TARGET Ilaprazole tablet Livzon Pharmaceutical Group Inc. phase 3 Proton pump inhibitor (PPI) H+/K+-ATPase (proton pump)
Nexium esomeprazole AstraZeneca marketed Proton pump inhibitor (PPI) Potassium-transporting ATPase 2001-02-20
Protonix pantoprazole Generic (originally Byk Gulden/Altana/Nycomed) marketed Proton pump inhibitor (PPI) ATP-binding cassette sub-family G member 2, Fatty acid synthase, Multidrug and toxin extrusion protein 1 2000-02-02
Protonix Pantoprazole Sodium Baxter marketed Proton pump inhibitor (PPI) (H+, K+)-ATPase enzyme system 2000-01-01
Pantoprazole Sodium Pantoprazole Sodium Pfizer marketed Proton pump inhibitor (PPI) (H+, K+)-ATPase enzyme 2000-01-01
Prevacid lansoprazole Generic (originally Takeda) marketed Proton pump inhibitor (PPI) ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase 1995-05-10
Prilosec omeprazole AstraZeneca (originally Astra AB) marketed Proton pump inhibitor (PPI) ATP-binding cassette sub-family G member 2, Cytochrome P450 1A2, Cytochrome P450 2C19 1989-09-14

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Proton pump inhibitor (PPI) class)

  1. AstraZeneca · 6 drugs in this class
  2. Takeda · 5 drugs in this class
  3. National Taiwan University Hospital · 4 drugs in this class
  4. Meridian Bioscience, Inc. · 4 drugs in this class
  5. Pfizer · 2 drugs in this class
  6. Chinese University of Hong Kong · 2 drugs in this class
  7. Sherief Abd-Elsalam · 2 drugs in this class
  8. Kwong Wah Hospital · 2 drugs in this class
  9. China-Japan Friendship Hospital · 1 drug in this class
  10. Charles Mel Wilcox, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ilaprazole tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/ilaprazole-tablet. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: